Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and irinotecan in locally advanced rectal cancer
NCT00216086Phase 2Terminated
- Start
- May 2005
- Primary completion
- May 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer. Started May 2005; status: terminated.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00216086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216086.